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Background: Cerebrovascular events that occur during structural and interventional procedures are awell known
risk which is associated with increased mortality. The FDA has approved the use of the Sentinel device in TAVR.
Hereby we report on our experience on the safety and efficacy of using Sentinel in a patient population undergo-
ing non-TAVR transcatheter procedures.
Methods: Retrospective analysis of a single center experience with using the Sentinel device for non-TAVR trans-
catheter procedures.
Results: We identified 33 patients (average age was 73.8 years, 36.7% females, and 30% with history of a prior
stroke) felt to be at high risk for cerebroembolic events that underwent Sentinel device placement. Sentinel
placement was successful in all patients. Examples of high risk features included high atheroma burden in the
aortic arch, left sided valve vegetations, intra-cardiac thrombi and severe left sided valve calcifications/thrombi.
No patients developed periprocedural stroke or vascular complications.
Conclusion: Overall, the use of Sentinel for non-TAVR indications appears feasible and safe. The use of cerebral
protection devices should be studied further in non-TAVR patients to establish its role and its benefits, especially
with expanding the number of non-TAVR transcatheter interventions.
© 2021 Published by Elsevier Inc.
1. Introduction
Catheter-based cardiovascular interventions continue to evolve as
new devices continue to expand the capabilities of interventional cardi-
ologists and to improve patient safety. The potential for embolization of
atheroma, vegetation of thrombus during catheter based cardiac inter-
ventions has long been recognized. Periprocedural stroke during trans-
catheter intervention is a rare but serious complication; it is associated
with high mortality and impaired quality of life [1].
Over the past decade, transcatheter aortic valve replacement (TAVR)
had emerged as a rapidly growing therapy for the treatment of aortic
stenosis (AS). Cerebrovascular events that occur during TAVR are a
well known risk which is associated with increased mortality. The vast
majority of neurological events in TAVRoccur in the peri-procedural pe-
riod [2] and are thought to be related to cerebral embolization and hy-
poperfusion [3]. Studies suggest that the highest rate of embolism
during TAVR is during valve positioning and deployment, and the sec-
ond highest rate of embolism is during balloon aortic valvuloplasty
[3]. Embolic protection devices (EPDs) were developed to help reduce
the risk of cerebrovascular events during transcatheter procedures. In
TAVR, the use of an FDA approved cerebral protection device (Sentinel
CPS®, Boston Scientific, Marlborough, MA, USA) has demonstrated re-
duced cerebral lesions as assessed with magnetic resonance imaging
(MRI) [4]. When performing TAVR with filter-based cerebral embolic
protection (CEP) devices, embolic debris is captured in 90% to 95% of pa-
tients [5].
The lessons of TAVR can provide valuable insights and developments
for other left sided cardiac procedures. The concept of trapping debris
and preventing distal embolization is an intuitively appealing concept
for other high risk procedures such as transcatheter mitral valve thera-
pies as well as other procedures with high risk for cerebrovascular
involvement.
We hereby report on our experience on the safety and efficacy of
using embolic protection devices in a patient population undergoing
transcatheter procedures felt to be at high risk for cerebrovascular em-
bolic events.
2. Methods
A single-center, retrospective, observational study was performed
with IRB approval. We identified 33 patients felt to be at high risk for
cerebroembolic events. In which EPD was felt to be indicated to reduce
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peri-procedural stroke risk. High risk features identified included high
atheroma burden in the aortic arch, left sided valve vegetations, intra-
cardiac thrombi and severe left sided valve calcifications/thrombi.
3. Results
Average CHA2DS2VASC score was 5.2 ± 1.2 (indicating elevated
peri-procedural stroke risk even in patients without atrial fibrillation
[6]), average age was 73.8 years, 36.7% females, and 30% with history
of a prior stroke. CEP with Sentinel™ CPSV® cerebral protection device
was used in all patients. Patients' selection to receive a Sentinel cerebral
protection device was based on clinical judgment regarding high risk of
peri-procedural embolism, see Table 1. The procedureswere performed
according to the CEP instructions for use. All patients had available CT
angiogram that was used to identify high-risk features that may pre-
clude the use of the CEP device. CT planning for Sentinel is key in
identifiying the size of the vessels (recommended vessel size of
9–15 mm for the right brachio-cephalic and 6.5–10 mm for the left ca-
rotid), anatomy of the neck vessels (whether a favorable angle, bovine
arch or howmuch calcium) and potential stenosis. Throughout the pro-
cedure, unfractionated heparin was administered to maintain an acti-
vated clotting time > 250 s. After the transcatheter procedure, the
filters were removed and their content underwent clinical examination.
All patients had successful placement of embolic protection device
without procedural complications or difficulties. No patients developed
periprocedural stroke or vascular complications.
4. Discussion
Due to the elevated risk of stroke in endo-vascular procedures, mul-
tiple EPDs were developed to help reduce this risk. In TAVR, the use of
the FDA approved Sentinel has demonstrated reduced cerebral lesions
as assessed with magnetic resonance imaging (MRI) [4] but is yet to
show a clinical reduction in cerebro-vascular events. An ongoing trial
is being performed to answer this very important question [PROTECTED
TAVR trial (NCT04149535)]. Data for theuse of EPDs is non-TAVR proce-
dures is scarce and outcomes are not known. Recently, a multi-center
European study demonstrated the efficacy and safety of using Sentinel
in patients presenting with left atrial appendage thomrbus who are
treated with trans-catheter left atrial appendage closure while using
the Sentinel device [7]. Our paper adds to the growing non-
randomized literature about the use of Sentinel for non-TAVR applica-
tions. More studies are needed to inform clinical practice and to
whether or not Sentinel is associated with reduction in clinical
endpoints.
5. Limitations
This is a retrospective analysis and carries the risk of confounding.
The lack of a control group is also a limitation. The decision to use CEP
in these cases was entirely based on physicians qualitative estimation
of stroke risk, which could be biased.
6. Conclusion and summary
High-risk catheter-based vascular and structural interventions carry
significant risk of stroke related presumably to embolization of ather-
oma, vegetation or thrombus. In TAVR, the use of a cerebral protection
device (Sentinel CPS®) has been proven to reduce cerebral lesions as
assessed with magnetic resonance imaging (MRI). We hereby report a
30 patient single-center studywherewe used Sentinel for non-TAVR in-
dications in selected high-risk individuals undergoing a variety of vas-
cular and structural procedures.
Overall, the use of Sentinel for non-TAVR indications appears feasi-
ble and safe. We had no strokes in our 30-patient series. The use of ce-
rebral protection devices should be studied further in non-TAVR
patients to establish its role and its benefits, especially with expanding
the number of non-TAVR transcatheter interventions.
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Table 1
Rationale for use of cerebral embolic protection in non-TAVR procedures.
Procedure performed Cases
(%)
Rational for CEP use
Transcatheter mitral valve
replacement
30.3 • Highly calcified valve leaflets
• Concern for valve thrombus
Percutaneous balloon mitral
valvuloplasty




18.2 • Large atheroma burden in aortic arch
Balloon aortic valvuloplasty 12.1 • Heavily calcified valve leaflets
Thrombus aspiration with
Angiovac system
6.1 • Thrombus in transit
• Large thrombus in aortic arch
Diagnostic coronary
angiogram
6.1 • Large aortic arch thrombus
• Aortic valve vegetations
Patent Foramen Ovale closure 3 • Deep venous thrombus with right to





3 • Deep venous thrombus with bidirec-
tional shunt through PFO and concern
for thrombus in transit
CEP = Cerebroembolic protection; PFO = patent formen ovale,
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